Redwire Awarded NASA Contract to Expand Pharmaceutical Drug Development in Space for Future Commercialization
“NASA has been an instrumental partner and customer as we’ve scaled our pharmaceutical drug manufacturing program significantly over the last year,” said John Vellinger, Redwire’s President of In-Space Industries. “Additional PIL-BOX investigations from NASA and commercial partners will enable Redwire to optimize the infrastructure to launch, test, manufacture, and return high-value space enabled pharmaceutical products and establish a new market in LEO”
With 28 units flown and processed to date, PIL-BOX provides pharmaceutical researchers with novel and flexible services to leverage the microgravity environment to grow small-batch crystals of protein-based pharmaceuticals and other key pharmaceutically relevant molecules. Previous spaceflight investigations indicate that growing crystals in space could yield a more uniform product with fewer imperfections, which can improve the drug discovery and development process. Previous investigations have focused on unlocking insights to improve treatments for cardiovascular disease, obesity, and diabetes.
About Redwire
Redwire Corporation (NYSE: RDW) is a global space infrastructure and innovation company enabling civil, commercial, and national security programs. Redwire’s proven and reliable capabilities include avionics, sensors, power solutions, critical structures, mechanisms, radio frequency systems, platforms, missions, and microgravity payloads. Redwire combines decades of flight heritage and proven experience with an agile and innovative culture. Redwire’s approximately 750 employees working from 17 facilities located throughout
View source version on businesswire.com: https://www.businesswire.com/news/home/20250325785635/en/
Media Contact:
Tere Riley
tere.riley@redwirespace.com
321-831-0134
OR
Investors:
investorrelations@redwirespace.com
904-425-1431
Source: Redwire Corporation